Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplitude Inc (AMPL) vs AstraZeneca plc (AZN) Price & Performance

Amplitude IncTrade
AstraZeneca plcTrade

Price performance (Past 24H)

Key statistics

Amplitude Inc vs AstraZeneca plc — how do they compare? Amplitude Inc trades at $12.37 (market cap $1.59B), while AstraZeneca plc trades at $158.28 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 156.1× Amplitude Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Amplitude Inc pays none. Which is the better fit depends on your goals.

AMPLAZN
Market Cap
$1.59B$248.14B
Sector
TechnologyHealth
52-Week High
$12.69$209.48
52-Week Low
$5.61$147.06
Enterprise Value
$1.45B$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplitude Inc

AMPL trades at $12.37, up 1.48% today, with a bullish technical signal from moving averages. Revenue grew to $343.21M in 2025, but net losses persist at -$88.54M. Analyst consensus is bullish with a $12.08 price target, supported by enterprise and AI-driven growth initiatives highlighted in recent earnings calls. The stock shows strong institutional buy ratings despite negative profitability metrics.

Outlook remains cautiously optimistic due to revenue growth and AI expansion, but risks include sustained losses, cash flow deficits, and ongoing legal investigations. The stock's valuation at P/S 4.49 may appeal if profitability improves, yet high P/B 11.64 signals premium pricing relative to book value.

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amplitude Inc

Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.

Read more on AMPL

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN